Wall Street analyst price targets, ratings consensus & upside potential · Updated Feb 28, 2026
Last 12 months price action with 12-month analyst target path
As of March 2, 2026, Biogen Inc. (BIIB) has a Wall Street consensus price target of $206.76, based on estimates from 47 covering analysts. With the stock currently trading at $191.82, this represents a potential upside of +7.8%. The company has a market capitalization of $28.15B.
Analyst price targets range from a low of $143.00 to a high of $250.00, representing a 52% spread in expectations. The median target of $200.00 aligns closely with the consensus average. The wide target spread reflects significant disagreement on fair value.
The current analyst consensus rating is Buy, with 25 analysts rating the stock as a Buy or Strong Buy,21 rating it Hold, and 1 rating it Sell or Strong Sell. The positive sentiment balance indicates moderate optimism about the stock prospects.
From a valuation perspective, BIIB trades at a trailing P/E of 21.7x and forward P/E of 12.2x. Analysts expect EPS to grow +78.9% over the next year.
Our proprietary valuation model, which blends historical multiples with forward estimates, suggests a base-case price target of $275.27, with bear and bull scenarios of $143.48 and $583.01 respectively. Model confidence stands at 58/100, reflecting moderate uncertainty in projections.
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorSee our Bear / Base / Bull DCF models and intrinsic value estimates.
View ValuationSee how BIIB stacks up against sector leader Agios Pharmaceuticals, Inc..
Start ComparisonThe consensus price target for BIIB is $206.76, close to the current price of $191.82 (7.8% implied move). Based on 47 analyst estimates, the stock appears fairly valued near current levels.
BIIB has a consensus rating of "Buy" based on 47 Wall Street analysts. The rating breakdown is predominantly bullish, with 25 Buy/Strong Buy ratings. The consensus 12-month price target of $206.76 implies 7.8% upside from current levels.
With a forward P/E of 12.1603x, BIIB trades at a relatively low valuation. The consensus target of $206.76 implies 7.8% appreciation, suggesting the market may be pricing in risks.
The most bullish Wall Street analyst has a price target of $250 for BIIB, while the most conservative target is $143. The consensus of $206.76 represents the median expectation. Our quantitative valuation model projects a bull case target of $583 based on optimistic growth and margin assumptions. These targets typically reflect 12-month expectations.
BIIB is heavily covered by Wall Street, with 47 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 25 have Buy ratings, 21 recommend Hold, and 1 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
The 12-month BIIB stock forecast based on 47 Wall Street analysts shows a consensus price target of $206.76, with estimates ranging from $143 (bear case) to $250 (bull case). The median consensus rating is "Buy". Our proprietary valuation model produces a base case fair value of $275, with bear/bull scenarios of $143/$583.
Our quantitative valuation model calculates BIIB's fair value at $275 (base case), with a bear case of $143 and bull case of $583. The model uses discounted cash flow analysis, historical growth rates, and margin mean-reversion to project FY+2 earnings, then applies an appropriate P/E multiple. The model confidence score is 58/100.
BIIB trades at a forward P/E ratio of 12.2x based on next-twelve-months earnings estimates compared to a trailing P/E of 21.7x. The lower forward P/E indicates analysts expect earnings growth. A forward P/E is useful for comparing valuations when earnings are expected to change significantly.
BIIB appears fairly valued according to analysts, with a "Buy" rating and minimal upside to the $206.76 target. Consider your investment thesis and risk tolerance. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
BIIB analyst price targets range from $143 to $250, a 52% wide spread indicating significant analyst disagreement. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $206.76 consensus represents the middle ground. Our model's $143-$583 range provides an independent fundamental perspective.